In a recent interview with Forbes' Matthew Herper, Dendreon's retiring chief scientist, David Urdal, weighs in on the lack of new drugs in the past few years. When Herper asks him why the drug business is "in such a profound innovation drought," Urdal says the dynamics of drug innovation have changed from when he began to work in the biotech industry.